{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:40:30Z","timestamp":1789220430656,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Suicidal behavior is a significant clinical concern in individuals with borderline personality disorder (BPD), but the effectiveness of pharmacotherapy on reducing suicide risk has remained unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To study the comparative effectiveness of different pharmacotherapies in preventing attempted or completed suicides in patients with BPD in Sweden.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting and Participants<\/jats:title>\n In this comparative effectiveness research study, nationwide Swedish register databases of inpatient care, specialized outpatient care, sickness absences, and disability pensions were used to identify patients aged 16 to 65 years with registered treatment contact due to BPD during 2006 to 2021. Data were analyzed from September to December 2022. A within-individual design was used, in which each patient was used as their own control to eliminate selection bias. To control protopathic bias, sensitivity analyses were conducted, in which the first 1 or 2 months of medication exposure were omitted from the analyses.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and Measures<\/jats:title>\n Hazard ratio (HR) for attempted or completed suicide.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 22\u202f601 patients with BPD (3540 [15.7%] men; mean [SD] age, 29.2 [9.9] years) were included. During the 16-year follow-up (mean [SD] follow-up, 6.9 [5.1] years), 8513 hospitalizations due to attempted suicide and 316 completed suicides were observed. Attention-deficit\/hyperactive disorder (ADHD) medication treatment, compared with its nonuse, was associated with a decrease in the risk of attempted or completed suicide (HR, 0.83; 95% CI, 0.73-0.95; false discovery rate [FDR]\u2013corrected\n P<\/jats:italic>\n \u2009=\u2009.001). Treatment with mood stabilizers did not have a statistically significant association with the main outcome (HR, 0.97; 95% CI, 0.87-1.08; FDR-corrected\n P<\/jats:italic>\n \u2009=\u2009.99). Antidepressant (HR, 1.38; 95% CI, 1.25-1.53; FDR-corrected\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and antipsychotic (HR, 1.18; 95% CI, 1.07-1.30; FDR-corrected\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) treatments were associated with an elevated risk of attempted or completed suicide. Of the investigated pharmacotherapies, treatment with benzodiazepines was associated with the highest risk of attempted or completed suicide (HR, 1.61; 95% CI, 1.45-1.78; FDR-corrected\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). These results remained similar when controlling for potential protopathic bias.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this comparative effectiveness research study of a Swedish nationwide cohort, ADHD medication was the only pharmacological treatment associated with reduced risk of suicidal behavior among patients with BPD. Conversely, the findings suggest that benzodiazepines should be used with care among patients with BPD due to their association with increased risk of suicide.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.17130","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T11:05:58Z","timestamp":1686135958000},"page":"e2317130","source":"Crossref","is-referenced-by-count":34,"title":["Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Johannes","family":"Lieslehto","sequence":"first","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"4","key":"zoi230515r1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1176\/appi.ajp.157.4.601","article-title":"Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study.","volume":"157","author":"Soloff","year":"2000","journal-title":"Am J Psychiatry"},{"key":"zoi230515r2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fpsyt.2020.00290","article-title":"Borderline personality disorder with depression confers significant risk of suicidal behavior in mood disorder patients: a comparative study.","volume":"11","author":"S\u00f6derholm","year":"2020","journal-title":"Front Psychiatry"},{"issue":"6","key":"zoi230515r3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/comp.2001.26271","article-title":"A 27-year follow-up of patients with borderline personality disorder.","volume":"42","author":"Paris","year":"2001","journal-title":"Compr Psychiatry"},{"issue":"1","key":"zoi230515r4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12436","article-title":"Deaths by suicide and other causes among patients with borderline personality disorder and personality-disordered comparison subjects over 24 years of prospective follow-up.","volume":"80","author":"Temes","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"zoi230515r5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-244X-10-109","article-title":"Psychiatric disorders and clinical correlates of suicidal patients admitted to a psychiatric hospital in Tokyo.","volume":"10","author":"Hayashi","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"7","key":"zoi230515r6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1017\/S0033291721001355","article-title":"Efficacy of dialectical behavior therapy for adolescent self-harm and suicidal ideation: a systematic review and meta-analysis.","volume":"51","author":"Kothgassner","year":"2021","journal-title":"Psychol Med"},{"issue":"8","key":"zoi230515r7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","article-title":"Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies.","volume":"22","author":"Stoffers-Winterling","year":"2020","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"zoi230515r8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/acps.2017.136.issue-3","article-title":"Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder.","volume":"136","author":"Mart\u00edn-Blanco","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"zoi230515r9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12888-019-2377-z","article-title":"Pharmacotherapy of borderline personality disorder: what has changed over two decades? a retrospective evaluation of clinical practice.","volume":"19","author":"Tim\u00e4us","year":"2019","journal-title":"BMC Psychiatry"},{"issue":"11","key":"zoi230515r10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012956.pub2","article-title":"Pharmacological interventions for people with borderline personality disorder.","volume":"11","author":"Stoffers-Winterling","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"zoi230515r11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1177\/02698811221131990","article-title":"Association between quetiapine use and self-harm outcomes among people with recorded personality disorder in UK primary care: a self-controlled case series analysis.","volume":"36","author":"Hayes","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"e1","key":"zoi230515r12","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1136\/ebmental-2022-300493","article-title":"Associations between antipsychotics and risk of violent crimes and suicidal behaviour in personality disorder.","volume":"25","author":"Herttua","year":"2022","journal-title":"Evid Based Ment Health"},{"issue":"6","key":"zoi230515r13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study.","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"6","key":"zoi230515r14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1521\/pedi.2010.24.6.812","article-title":"Comorbid attention-deficit\/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder.","volume":"24","author":"Ferrer","year":"2010","journal-title":"J Pers Disord"},{"key":"zoi230515r15","doi-asserted-by":"publisher","first-page":"g3769","DOI":"10.1136\/bmj.g3769","article-title":"Drug treatment for attention-deficit\/hyperactivity disorder and suicidal behaviour: register based study.","volume":"348","author":"Chen","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"zoi230515r16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00787-010-0140-6","article-title":"European guidelines on managing adverse effects of medication for ADHD.","volume":"20","author":"Graham","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"5","key":"zoi230515r17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/acps.v141.5","article-title":"Validity of the personality disorder diagnosis in the Swedish National Patient Register.","volume":"141","author":"Kouppis","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"zoi230515r18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods\u2014a second generation method (PRE2DUP).","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"zoi230515r19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-019-0695-y","article-title":"Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.","volume":"19","author":"Prada-Ramallal","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"zoi230515r20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2021.03.005","article-title":"Registry-based studies: what they can tell us, and what they cannot.","volume":"45","author":"Taipale","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"zoi230515r22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/rssb.1995.57.issue-1","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"6","key":"zoi230515r23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopsych.2019.12.003","article-title":"Medication for attention-deficit\/hyperactivity disorder and risk for suicide attempts.","volume":"88","author":"Chang","year":"2020","journal-title":"Biol Psychiatry"},{"key":"zoi230515r24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-018-0086-8","article-title":"Emotion dysregulation in attention-deficit\/hyperactivity disorder and borderline personality disorder.","volume":"5","author":"Moukhtarian","year":"2018","journal-title":"Borderline Personal Disord Emot Dysregul"},{"key":"zoi230515r25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40479-019-0108-1","article-title":"Emotion dysregulation in adults suffering from attention deficit hyperactivity disorder (ADHD), a comparison with borderline personality disorder (BPD).","volume":"6","author":"R\u00fcfenacht","year":"2019","journal-title":"Borderline Personal Disord Emot Dysregul"},{"issue":"9","key":"zoi230515r26","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","article-title":"Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders.","volume":"48","author":"Bloch","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"zoi230515r27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamapsychiatry.2020.3598","article-title":"Association of borderline personality disorder criteria with suicide attempts: findings from the Collaborative Longitudinal Study of Personality Disorders over 10 years of follow-up.","volume":"78","author":"Yen","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi230515r28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/YIC.0000000000000021","article-title":"Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices.","volume":"29","author":"Knappich","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"zoi230515r29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.31887\/DCNS.2013.15.2\/lripoll","article-title":"Psychopharmacologic treatment of borderline personality disorder.","volume":"15","author":"Ripoll","year":"2013","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"zoi230515r30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/ajp.142.1.98","article-title":"Alprazolam-induced dyscontrol in borderline personality disorder.","volume":"142","author":"Gardner","year":"1985","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi230515r31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.","volume":"45","author":"Cowdry","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"25","key":"zoi230515r32","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials.","volume":"342","author":"Benson","year":"2000","journal-title":"N Engl J Med"},{"key":"zoi230515r21","doi-asserted-by":"crossref","DOI":"10.4135\/9781412993869","volume-title":"Fixed Effects Regression Models","author":"Allison","year":"2009"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2805752\/lieslehto_2023_oi_230515_1685466882.92944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T11:06:02Z","timestamp":1686135962000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17130","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}